Clik here to view.
Vitruvianがフレックスグローバルの過半数株式をブリッジポイントより取得
英アマーシャム & 米ペンシルベニア州マルバーン (ビジネスワイヤ） — ライフサイエンス産業向けの電子治験マスターファイル（eTMF）システム／サービスの提供に関し世界的に有名なソートリーダー／専門家集団であるフレックスグローバルは本日、Vitruvian...
View ArticleClik here to view.
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Vemlidy® for...
FOSTER CITY, Calif. Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Vemlidy® (tenofovir alafenamide) 25mg, a...
View ArticleClik here to view.
Completion of a Reserved Share Capital Increase of Median Technologies to...
SOPHIA ANTIPOLIS, France Regulatory News: Median Technologies (Paris:ALMDT), the Imaging Phenomics™ Company announced in a press release dated November 16th, 2016 that it had entered into an...
View ArticleClik here to view.
Ferring and IMAB Sign Licensing Agreement Granting IMAB Exclusive Rights in...
SAINT-PREX, Switzerland Ferring Pharmaceuticals and IMAB today announced that they have signed a licensing agreement which grants IMAB exclusive rights to olamkicept (pINN) in Asia. Olamkicept is a...
View ArticleClik here to view.
和铂医药全资收购全球医药行业核心技术平台，打造专注肿瘤免疫领域的世界顶级生物科技公司
美国马萨诸塞州剑桥、中国上海、荷兰鹿特丹 (美国商业资讯)– 和铂医药，一家总部位于中国的新创公司，今天宣布以现金加股权的方式收购总部位于荷兰的Harbour Antibodies BV公司，并将在此基础上，打造专注肿瘤免疫领域的世界顶级生物医药公司。新公司将运用其拥有全面专利保护的Harbour...
View ArticleClik here to view.
Harbour BioMed Acquires Harbour Antibodies to Create Global, Oncology-focused...
CAMBRIDGE, Mass. & SHANGHAI & ROTTERDAM, The Netherlands Harbour BioMed, a recently established Shanghai-based company, today announced it has acquired Harbour Antibodies BV for cash and an...
View ArticleClik here to view.
Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and...
CAMBRIDGE, Mass. & TOKYO Akebia Therapeutics, Inc. (NASDAQ: AKBA) and Otsuka Pharmaceutical Co., Ltd. today announced they have entered into a collaboration and license agreement in the U.S. for...
View ArticleClik here to view.
Clik here to view.
Acelity to Sell LifeCell Business Unit to Allergan
SAN ANTONIO Acelity L.P. today announced a definitive agreement with Allergan for the acquisition of Acelity’s LifeCell business unit for $2.9 billion in cash. Upon completion of the transaction,...
View ArticleClik here to view.
ノボキュア・オプチューン（NovoTTF-100A）が 神経膠芽腫の治療用機器として厚生労働省より初発患者への適用拡大を承認
ジャージー州セント・ヘリア発 （ビジネスワイヤ） — ノボキュア社（NASDAQ:...
View ArticleClik here to view.
Exelixis and Ipsen amend exclusive licensing agreement for the...
PARIS & SOUTH SAN FRANCISCO, Calif. Regulatory News: Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today jointly announced an amendment to the exclusive collaboration and...
View ArticleClik here to view.
Octapharma向WFH人道主义援助项目捐赠Nuwiq®，使发展中国家的血友病A患者能够得到治疗
瑞士拉亨 (美国商业资讯) — Octapharma自豪地宣布，该公司已向世界血液科联盟(WFH)人道主义援助项目捐赠了450万份Nuwiq®，Nuwiq®是该公司的第四代人类细胞系衍生重组第VIII因子产品。...
View ArticleClik here to view.
オクタファルマ、発展途上国の血友病A患者が利用できるようNuwiq®をWFH人道支援プログラムに寄付
スイス・ラッヘン （ビジネスワイヤ） — オクタファルマは、当社の第4世代ヒト細胞株由来組み換え型第VIII因子製剤（Nuwiq®）450万ユニットを世界血友病連盟（WFH）の人道支援プログラムに慈善活動として寄付したとことを発表します。...
View ArticleClik here to view.
Kubota Pharmaceutical Holdings Signs Letter of Intent to Form a Joint Venture...
TOKYO Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596, “Kubota Pharma”), a clinical-stage ophthalmology company committed to translating innovation into a diverse portfolio of drugs and devices...
View ArticleClik here to view.
BIT Group Opens IVD-Focused Contract Manufacturing Facility in China
SCHWALBACH, Germany On December 9, BIT Group celebrated the official opening of EMD Shenzhen, Ltd., – its second Chinese manufacturing operation in Shenzhen, China and a joint venture with EDAN...
View ArticleClik here to view.
BridgeBio Pharma成立，专注于治疗基因疾病的精准药物
加州帕罗奥图 (美国商业资讯) — 总部位于加州的BridgeBio Pharma已走出隐身模式，以披露有关其开发治疗基因疾病新药创新之道的更多细节。这些疾病通常具有遗传性和个体罕见性，整体而言，单在美国就有数千万名病患受到此类疾病的摧残，其中许多是儿童。公司成立于2015年，主要重点是上市前产品，运用其采购和运营优势，在开发的各个阶段寻找和构建价值。 BridgeBio...
View ArticleClik here to view.
GI Dynamics, Inc., Appoints Oern R. Stuge, MD, Amid Change to Company’s Board...
BOSTON & SYDNEY GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, today...
View ArticleClik here to view.
iCarbonX Expands Digital Life Alliance to Accelerate Development of Global...
SHENZHEN, China At the first Digital Life Summit, iCarbonX founder Jun Wang announced that seven companies have joined iCarbonX’s Digital Life Alliance and will collaborate to give people a deeper...
View ArticleClik here to view.
Takeda and PvP Biologics Announce Development Agreement around Novel...
OSAKA, Japan & SAN DIEGO & SEATTLE Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) and PvP Biologics, Inc. (“PvP”) today announced a global agreement for the development of...
View ArticleClik here to view.
武田薬品とPvP Biologicsによるセリアック病治療薬の開発に関する提携契約の締結について
大阪 & サンディエゴ & シアトル （ビジネスワイヤ） — 武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）とPvP Biologics,...
View Article